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Abstract
Background: Efficient control of tuberculosis (TB) requires development of strategies that can enhance efficacy of the
existing vaccine Mycobacterium bovis Bacille Calmette Guerin (BCG). To date only a few studies have explored the potential
of latency-associated antigens to augment the immunogenicity of BCG.
Methods/Principal Findings: We evaluated the protective efficacy of a heterologous prime boost approach based on
recombinant BCG and DNA vaccines targeting a-crystallin, a prominent latency antigen. We show that ‘‘rBCG prime - DNA
boost’’ strategy (R/D) confers a markedly superior protection along with reduced pathology in comparison to BCG
vaccination in guinea pigs (565 fold and 45 fold reduced CFU in lungs and spleen, respectively, in comparison to BCG
vaccination). In addition, R/D regimen also confers enhanced protection in mice. Our results in guinea pig model show a
distinct association of enhanced protection with an increased level of interleukin (IL)12 and a simultaneous increase in
immuno-regulatory cytokines such as transforming growth factor (TGF)b and IL10 in lungs. The T cell effector functions,
which could not be measured in guinea pigs due to technical limitations, were characterized in mice by multi-parameter
flow cytometry. We show that R/D regimen elicits a heightened multi-functional CD4 Th1 cell response leading to enhanced
protection.
Conclusions/Significance: These results clearly indicate the superiority of a-crystallin based R/D regimen over BCG. Our
observations from guinea pig studies indicate a crucial role of IL12, IL10 and TGFb in vaccine-induced protection. Further,
characterization of T cell responses in mice demonstrates that protection against TB is predictable by the frequency of CD4
T cells simultaneously producing interferon (IFN)c, tumor necrosis factor (TNF)a and IL2. We anticipate that this study will
not only contribute toward the development of a superior alternative to BCG, but will also stimulate designing of TB
vaccines based on latency antigens.
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Introduction
The ability of Mycobacterium tuberculosis to survive the hostile
immune responses and persist in a non-replicating dormant state
is fundamental to its success as a human pathogen. One third of
the world’s population is asymptomatically infected with M.
tuberculosis and represents an enormous pool of latent tuberculosis
(TB) infections. Reactivation of these latent infections, which is
responsible for majority of TB cases, contributes significantly to
the problems associated with the incidence, transmission and
pathogenesis of TB [1]. M. bovis Bacille Calmette Guerin (BCG),
which provides consistent protection against severe forms of
child hood TB, loses its potency gradually resulting in an
inadequate protection in adults and elderly people [2]. Thus, for
an efficient global control of TB, we require to develop new
vaccination strategies to improve and sustain the protective
efficacy of BCG.
Transcriptome and proteome analysis of M. tuberculosis
revealed that a-crystallin (acr, Rv2031c), a member of DosR-
DosS/DosT dormancy regulon, represents one of the most
abundantly produced proteins during exposure to hypoxia,
nutrient starvation and transition of actively dividing bacilli to a
dormant state [3,4]. Besides, latently infected individuals
(healthy PPD+ and household contacts) exhibit increased
lympho-proliferative and IFNc response to a-crystallin as
compared to patients with active TB [5]. These observations
signify a crucial role of a-crystallin in the elicitation of protective
immune responses and maintenance of a disease free state in
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these subjects, thus, making this antigen an attractive target for
the development of new TB vaccines.
We have previously reported a DNA vaccine expressing a-
crystallin (DNAacr) that protected guinea pigs against M.
tuberculosis infection, however, it could not surpass the protective
efficacy of BCG [6]. Thus, in the present study, we have developed
an rBCG strain over-expressing a-crystallin (rBCGacr) and
evaluated its protective efficacy in guinea pigs either alone or in
combination with DNAacr in a heterologous prime boost regimen
against M. tuberculosis challenge. In addition, we attempted to
establish an association between the dynamic changes in the
pulmonary cytokine milieu and vaccine-induced protection.
Further, we delineated an association between multi-functional
T cell responses and protective efficacy of these vaccine regimens.
This study shows that vaccination regimens designed to target
latency-associated antigens can elicit a superior protective
immunity than BCG against TB.
Results
Analysis of expression and in vitro growth of rBCG strain
over-expressing a-crystallin
rBCG strain over-expressing a-crystallin of M. tuberculosis was
prepared by transformation of BCG with a recombinant plasmid
(pSD5.hsp65.acr) engineered to over-express a-crystallin under the
transcriptional control of promoter of the hsp65 gene of M. leprae
(Fig. 1A). A comparison of the protein expression in the lysates of
BCG and rBCGacr harvested from a culture of A600 nm 0.8–1.0 by
densitometry analysis of the immuno-blots revealed a considerably
higher expression of a-crystallin in rBCG (15 fold) when compared
with the parental BCG strain (Fig. 1B).
To determine whether the higher production of a-crytallin by
rBCG influences its in vitro growth, we monitored the A600 nm of
BCG and rBCG cultures over a period of 19 days (Fig. 1C). Both
BCG and rBCG exhibited a comparable growth pattern till late
log phase (till day 11). Although, rBCG failed to achieve as high
A600 nm as that by wild type BCG at the end of log phase (day 12),
it maintained the saturation A600 nm for a considerably longer
duration than the wild type BCG. In the death phase, while, BCG
showed a sharp decline in A600 nm, the corresponding decline in
the case of rBCG was considerably slower. The in vitro growth
kinetics indicates that over-expression of a-crystallin in rBCG
perhaps protects the aging bacteria to some extent against autolysis
owing to the chaperonic activity of a-crystallin, which is known to
stabilize the cell wall and intracellular structures. These observa-
tions are in coherence with a previous study, which showed a
slower decline in the viability following the end of log-phase
growth of recombinant M. tuberculosis over-expressing this protein
[7].
Enhanced protection conferred by a- crystallin based
heterologous prime boost vaccination
To evaluate the protective efficacy of a-crystallin based vaccine
regimens, we first determined the influence of vaccine-induced
immunity on the multiplication of M. tuberculosis. For this, 12 weeks
after the primary immunization, guinea pigs were infected with
50–100 bacilli by aerosol route and euthanized at 10 weeks post-
infection (Exp-I). As described in a seminal study by EU TB
vaccine cluster, involving evaluation of 24 TB vaccine regimens in
guinea pig model, the dose of infection employed in this study not
only allowed induction of measurable clinical illness in 100% of
control animals but also permitted discrimination with respect to
BCG within a relatively short time frame (10 weeks) [8]. Under
these experimental conditions, all the vaccine regimens resulted in
a significantly reduced bacillary load in lungs and spleen, when
compared to the unvaccinated animals (p,0.05) (Fig. 2A).
Immunization with BCG (0.94 log10 and 1.48 log10 fewer bacilli
in lungs and spleen, respectively) and rBCG (1.34 log10 and 1.63
log10 fewer bacilli in lungs and spleen, respectively) resulted in a
comparable reduction in bacillary load when compared to the
unvaccinated animals. However, the ‘rBCG prime-DNA boost’
regimen (R/D) conferred a far greater protection with a markedly
reduced bacillary count when compared to the unvaccinated
animals (2.28 log10 and 3.2 log10 fewer bacilli in lungs and spleen,
respectively). Moreover, the magnitude of protection by R/D
regimen was especially noteworthy, as it resulted in 1.34 log10 and
1.72 log10 fewer bacilli in lungs and spleen, respectively in
comparison to BCG vaccination (p,0.05), (Fig. 2A).
Having established the superiority of a-crystallin based R/D
regimen in restricting the bacillary multiplication in short-term
experiment; we sought to evaluate the sustenance of protection by
extending the post-challenge period to 16 weeks (Exp-II). As
disease severity increased with time, one third of the unvaccinated
animals (2/6) succumbed to the disease. Although, no mortality
was observed in the BCG group, the bacillary load in the lungs
Figure 1. Development of rBCG strain over-expressing
a-crystallin and analysis of expression and in vitro growth. (A)
A Mycobacteria - Escherichia coli shuttle plasmid pSD5.hsp65.acr was
engineered to over-express a-crystallin under transcriptional control of
the promoter of hsp65 gene of M. leprae. The recombinant plasmid was
electroporated into M. bovis BCG to generate rBCGacr strain. (B) The
whole cell lysates of BCG and rBCGacr (grown to A600 nm of 0.8–1.0)
were analysed for the expression of a-crystallin by SDS-PAGE and
immuno-blotting by using antigen specific antibodies. By densitometric
analysis, rBCGacr was found to produce a considerably higher level of
16 kDa a-crystallin protein in comparison to wild type BCG strain (,15
fold). (C) Growth kinetics of BCG and rBCG during 19 days of culture in
7H9 medium. The A600 nm of broth culture was plotted against time.
Data points are presented as mean 6 SE of duplicate cultures.
doi:10.1371/journal.pone.0018773.g001
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and spleens of BCG vaccinated animals was observed to be as
much as in the case of unvaccinated animals (surviving ones)
indicating a considerable decline in the protection conferred by
BCG vaccination on extending the post-challenge period to 16
weeks (Fig. 2B). In contrast, rBCG regimen still resulted in a
considerably reduced bacillary load in the lungs (1.87 log10 fewer
bacilli), but not in spleen, when compared to the unvaccinated
animals. However, remarkably the R/D regimen continued to
impart a significant protection as was evident from a substantially
reduced bacillary load both in lungs (by 2.75 log10) and spleen (by
1.65 log10) in comparison to the BCG vaccinated animals
(p,0.01), (Fig. 2B). The influence of boosting on bacillary
reduction in case of R/D regimen was antigen specific, since no
additional benefit was observed in case of rBCG prime – vector
boost (R/V) regimen over rBCG vaccination.
In parallel, we also determined M. tuberculosis antigen load in
lung tissues by in situ localization of Ag85 complex proteins that in
addition to indicating the presence of live bacilli, served as a
marker of dead bacilli, bacillary remnants as well as secreted
antigens (a source of inflammation) [9]. We observed a strong
positive correlation between antigen load and bacillary count
(r = .78, p,0.001). Particularly, in concordance with the reduced
bacillary load, animals vaccinated with R/D regimen exhibited a
minimal antigen load both at 10 and 16 weeks post infection in
comparison to saline and BCG immunized animals (Fig. 3). Taken
together, these observations confirm that a-crystallin based R/D
regimen not only exhibited a greater and sustained control on
bacillary multiplication but was also efficient in antigenic clearance
from the site of infection.
Reduced gross and histopathological lesions following
prime boost vaccination
We next examined the influence of prime boost vaccination on
pathological changes in various organs of guinea pigs. At 10 weeks
post-infection, unvaccinated animals exhibited severe pathology in
all the organs. Immunization of animals with BCG as well as
rBCG resulted in a significant decline in the number of gross
lesions in the lungs and spleen compared to the unvaccinated
Figure 2. Protection by a-crystallin based prime boost
regimens against M. tuberculosis challenge. The figure depicts
the bacillary load in lungs and spleen of guinea pigs at (A) 10 weeks
(n = 5) and (B) 16 weeks (n = 6) post-infection. Animals vaccinated with
R/D regimen exhibited a significantly lower bacillary load in lung and
spleen when compared to the unvaccinated as well as BCG vaccinated
animals at both 10 weeks and 16 weeks post-infection. Log10 CFU is
represented by box plot, wherein median values are denoted by
horizontal line, the mean is represented by ‘+’, inter quartile range by
boxes, and the maximum and minimum values by whiskers. R/D, rBCG
prime – DNAacr boost; R/V, rBCG prime – vector boost. (*, p,0.05, **,
p,0.01 and ***, p,0.001, when compared to the saline group, One-
way ANOVA).
doi:10.1371/journal.pone.0018773.g002
Figure 3. a-crystallin based prime boost vaccination reduces
antigen load in pulmonary granulomas. The representative
photomicrographs of lung sections show immuno-histochemical
staining (brown color) for Ag85 complex proteins in pulmonary
granulomas at (A) 10 weeks and (B) 16 weeks post-infection. (A)
Animals in the unvaccinated group exhibited extensive staining within
the granulomatous regions; BCG and rBCGacr vaccinated animals
showed moderate and comparable staining; animals vaccinated with
R/D regimen showed a reduced antigen staining, when compared to
BCG vaccinated animals. (B) Unvaccinated animals and BCG vaccinated
animals showed similar staining pattern as observed at 10 weeks;
rBCGacr and R/D vaccinated animals showed a significantly reduced
antigen load. Scale bar represents 1 mm. Extent (Q) of staining was
measured by light microscopy [Q= intensity (I)6area (A) of staining] and
represented graphically as median (6 inter quartile range). R/D, rBCG
prime – DNAacr boost. (*, p,0.05; **, p,0.01, when compared to the
unvaccinated animals, Mann-Whitney U test).
doi:10.1371/journal.pone.0018773.g003
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animals. Moreover, liver of animals from both these groups
showed no evident gross lesions (Fig. 4A). Noticeably, animals
vaccinated with R/D regimen exhibited only a minimal
pulmonary involvement with no evident gross lesions in liver as
well as spleen.
Morphometric analysis of lung and liver sections further
substantiated the gross pathological observations. At 10 weeks
post-infection, unvaccinated animals exhibited extensive coalesc-
ing granulomas (,60%) encompassing scattered areas of necrosis
in lungs along with lymphocytic infiltration in the hepatic lobules
(,43%) (Fig. 5A). Animals vaccinated with BCG and rBCG not
only exhibited reduced pulmonary consolidation (,32% and 21%,
respectively), they also showed markedly reduced hepatic inflam-
mation (,5%). Among the vaccinated groups, animals belonging
to R/D group showed minimal pulmonary consolidation (,11%),
with the presence of only a few scattered areas of diffused
infiltration, primarily in the inter-alveolar septa and peribronchial
or perivascular regions, with no evidence of inflammation in liver
(Fig. 5A).
The protective effect of a-crystallin based prime boost
vaccination was further substantiated by pathological observations
in Exp-II. While BCG and rBCG vaccinated guinea pigs exhibited
an increased disease severity with time, animals vaccinated with
R/D regimen exhibited minimal gross lesions in liver and spleen
along with a considerably lower pulmonary pathology compared
to BCG and rBCG vaccinated animals (Fig. 4B). Histological
analysis also supported the gross pathological findings (Fig. 5B).
Further, while, unvaccinated animals exhibited obliteration of
alveolar structure due to widespread collagen deposition in the
granulomatous areas in the lungs, no evident signs of collagen
deposition were observed in the lungs of animals vaccinated with
R/D regimen at both 10 and 16 weeks post-infection (Fig. 6).
Collagen deposition in BCG and rBCG vaccinated animals was
although significantly reduced when compared to the unvaccinat-
ed animals (p,0.05), it remained markedly higher in comparison
to R/D vaccinated animals (Fig. 6). These observations suggest
that vaccination with R/D regimen, in addition to reducing the
bacillary burden, imparts a marked protection against collateral
pathological damage.
Vaccination induced cytokine response and its influence
on immunopathology and protection
Considering the observed differences in the levels of protection
imparted by various a-crystallin based vaccine regimens, we next
attempted to delineate the immunological responses that differen-
tiate a successful vaccine regimen from the one that fails to provide
consistent protection over a prolonged period of time. To address
this issue, profiling of various pro and anti-inflammatory cytokines
was carried out by real time RT-PCR of the mRNA isolated from
the lungs of guinea pigs at 10 and 16 weeks post-infection. At 10
weeks post-infection BCG vaccinated animals exhibited very low
levels of all the cytokines studied (IFNc, TNFa, TGFb, IL10 and
IL12) (Fig. 7A). At this time point, rBCG vaccinated animals
exhibited relatively higher levels of IFNc, TNFa, TGFb and IL10
compared to BCG vaccinated animals. However, the level of IL12
in rBCG-vaccinated animals remained relatively lower compared
to the BCG vaccinated animals. Similarly, animals vaccinated with
R/D prime boost regimen also exhibited relatively higher levels of
IFNc, TNFa and TGFb compared to BCG vaccinated animals
along with a relatively lower level of IL12 (Fig. 7A).
At 16 weeks post-infection, unvaccinated animals exhibited a
marked up-regulation in the levels of IFNc and TNFa in
comparison to 10 weeks post-infection. Similarly, BCG immu-
nized animals exhibited a significant up-regulation in the levels of
inflammatory cytokines (IFNc and TNFa) (p,0.05), when
compared to 10 weeks time point (Fig. 7B). However, the levels
Figure 4. Reduction in gross pathological damage by a-crystallin based prime boost regimen. The figure depicts representative
photographs and graphical depiction of gross scores of lung, liver and spleen of guinea pigs at (A) 10 weeks (n = 5) and (B) 16 weeks (n = 6) post-
infection. Based on the extent of involvement, number and size of tubercles, areas of inflammation and necrosis; gross pathological scores were
graded from 1–4 as described in materials and methods and represented graphically. (A) BCG, rBCGacr and R/D regimens resulted in a significant
reduction in pathological lesions in lung and liver compared to the saline control; animals in R/D group also showed a significantly reduced spleen
pathology, when compared to BCG vaccinated animals. (B) Animals in R/D group showed minimal pathology in all the organs, when compared to
BCG vaccinated animals. Each point represents score for an individual animal and the bar depicts median (6 inter quartile range) for each group.
Missing data points represent the animals that succumbed to disease before euthanasia. R/D, rBCG prime – DNAacr boost; R/V, rBCG prime – vector
boost. (*, p,0.05 and **, p,0.01, when compared to the saline group, Mann-Whitney U test).
doi:10.1371/journal.pone.0018773.g004
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of IL10, IL12 and TGFb in these groups remained unaltered with
time. Contrary to BCG, on extending the time of evaluation to 16
weeks post-infection, rBCG vaccination resulted in a considerable
decline in the levels of IFNc and IL10; a significant increment in
the levels of IL12 (p,0.05), while the levels of TNFa and TGFb
remained unaltered. Notably, animals vaccinated with R/D
regimen exhibited a marked up-regulation in the expression of
all the cytokines investigated, with the highest up-regulation
noticed in case of IL12, when compared to the 10 weeks time
point (Fig. 7B).
Thus, R/D regimen, which imparted the highest protection
amongst all the vaccine regimens, exhibited the most striking
pattern of cytokine expression. The animals from this group not
only exhibited a significant up-regulation of pro-inflammatory
cytokines but the levels of anti-inflammatory cytokines were also
elevated in comparison to BCG and rBCG vaccinated animals
(Fig. 7B). While, we did not observe any correlation between an
increase in the level of IFNc alone with the degree of protection, it
was evident that simultaneous up-regulation of IL12 as well as
anti-inflammatory cytokines like TGFb and IL10 is crucial for a
sustained protection as observed in the case of R/D regimen. Our
data, thus suggests that to understand the role of cytokines in
protective immunity and to correlate the cytokine milieu with the
vaccine induced protection, it may be prudent to take the dynamic
interplay of various cytokines into consideration instead of
measuring a single cytokine, such as IFNc.
Induction of multi-functional CD4 Th1 cell response by R/D
regimen confers enhanced protection in murine model
Although, dynamic changes in the pulmonary cytokine milieu
provided crucial information regarding the involvement of these
cytokines in protection against TB, non-availability of immuno-
logical reagents in guinea pigs limited our ability to study the T cell
effector functions and define the immuno-correlates of protection
in guinea pigs. Thus, we next investigated the immune responses
induced by various vaccine regimens along with the evaluation of
their protective efficacy in murine model.
Murine model has been extensively employed to understand the
role of Th1 responses in M. tuberculosis infection and vaccine-
induced protection [10,11]. While, generation of effector cyto-
kines, such as IFNc and TNFa by the Th1 cells are known to be
crucial for the resolution of M. tuberculosis infection, IL2 production
by these T helper cells aids in the maintenance of memory
immunity against infection [12,13]. Based on this, we carried out a
functional analysis of cytokine producing CD4 T cells by multi-
parameter flow cytometry. We assessed the Th1 cell response by
Figure 5. Reduced granulomatous inflammation following M. tuberculosis infection in animals vaccinated with R/D regimen.
Representative photomicrographs of H&E stained lung and liver sections showing granulomatous pathology at (A) 10 weeks (n = 5) and (B) 16 weeks
(n = 6) post-infection. Lung: at both the time points, unvaccinated animals showed the presence of coalescing granulomas with extensive necrosis;
BCG and rBCG groups showed moderate involvement with well-organized discrete granulomas with or without central necrosis; animals in R/D group
showed reduced granulomatous infiltration with a few diffused aggregates of inflammatory cells in the peribronchial and perivascular areas. Liver:
unvaccinated animals showed moderate to high granulomatous lesions; BCG vaccinated animals showed minimal inflammatory aggregates; all the
regimens based on a-crystallin showed negligible hepatic inflammation. Scale bar represents 2 mm. Granuloma % were measured by light
microscopy and graphically represented by box plot (notations are described in the legend of Fig. 1). R/D, rBCG prime – DNAacr boost; R/V, rBCG
prime – vector boost. (*, p,0.05, **, p,0.01, when compared to the saline group, Mann-Whitney U test).
doi:10.1371/journal.pone.0018773.g005
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staining the spleen cells for CD4 T cell marker along with IFNc,
TNFa, and IL2 after stimulation with PPD and a-crystallin. Based
on the expression of various combinations of these cytokines, CD4
T cells were divided in to 7 distinct populations as described in
[14], which define the quality of immune response. The immune
responses were compared among BCG, rBCG and R/D groups at
12 weeks after the primary immunization (at the time of infection)
with respect to the sham immunized animals.
At 12 weeks post-immunization, although a comparable
frequency of CD4 and CD8 T cells was observed in splenocytes
isolated from all the groups (data not shown), a marked functional
heterogeneity was observed in the CD4 T cell subsets isolated from
different groups in terms of their ability to produce IFNc, TNFa
and IL2 (Fig. 8). R/D vaccination resulted in a very high total
frequency of PPD specific IFNc+, TNFa+ or IL2+ CD4 T cells
when compared with BCG, rBCG as well as sham immunized
animals (Fig. 8A). In addition, the total frequency of a-crystallin
specific TNFa producing CD4 T cells was also considerably
higher in R/D group (Fig. 8A).
A more comprehensive functional analysis of CD4 T cells
producing various combinations of cytokines revealed the presence
of a markedly higher frequency of PPD as well as a-crystallin
specific 3+ (IFNc+TNFa+ IL2+) and 2+ (producing any two
cytokines) CD4 T cells in R/D vaccinated animals compared to
BCG, rBCG and sham immunized animals (Fig. 8B and 8C).
Among the 2+ CD4 T cells, a considerably higher frequency of a-
crystallin specific TNFa+IL2+ and IFNc+TNFa+ cells were
observed in case of R/D vaccinated animals (Fig. 8B). In addition,
R/D vaccinated animals also exhibited a relatively higher
frequency of PPD specific IFNc+TNFa+ CD4 T cells. On
comparing different vaccinated groups, although, we did not
notice any considerable difference in the median fluorescence
intensities (MFIs) of 3+ CD4 T cells, integrated MFI (iMFI=
%frequency6MFI) for all the three cytokines of these cells
remained markedly higher in R/D vaccinated animals compared
to rest of the groups (Fig. 8D). We also looked for a potential role
of CD8 T cells following a similar analysis, however, we did not
observe any characteristic association of vaccine induced protec-
tion with these cells in this study (data not shown).
Next, we evaluated the protective efficacy of various vaccine
regimens in mice at 2, 4 and 10 weeks post-infection. On
comparing the protective efficacy of these vaccine regimens at 2
weeks post infection, rBCG vaccination did not result in any
significant reduction in bacillary load in the lungs when compared
to the sham immunized animals, although, it slowed down the
dissemination of bacilli to spleen (Fig. 9). However, the R/D
regimen exhibited the highest protection among all the vaccinated
groups (Fig. 9). In addition to significantly reducing the bacillary
load in lungs compared to the unvaccinated animals (0.55 log10
fewer bacilli, p,0.01), this regimen also slowed down the
dissemination of bacilli to spleen to the extent that no bacillary
growth was detected in spleen at 2 weeks post-infection. These
observations are especially noteworthy, since, at such an early time
point, BCG vaccination, as seen in this study (Fig. 9) and in
another seminal study [15] does not begin to exhibit any
significant control on bacillary multiplication in lung or spleen in
comparison to the sham immunization.
By 4 weeks post-infection, all the vaccine regimens resulted in a
marked reduction in lung and spleen bacillary load when
compared to sham immunization (Fig. 9). However, R/D regimen
conferred the highest protection with a markedly reduced bacillary
count when compared to the unvaccinated animals [1.16 log10 and
1.05 log10 fewer bacilli in lungs (p,0.001) and spleen (p,0.01),
respectively]. Moreover, the magnitude of protection in lungs by
R/D regimen was especially noteworthy, as it resulted in 0.52
log10 fewer bacilli in lungs in comparison to BCG vaccination
(p,0.05). At this time point, rBCG vaccination however conferred
a comparable protection to that observed in case of BCG
vaccination.
Further, at 10 weeks post-infection, R/D regimen continued to
impart the highest protection, as was evident from a markedly
reduced bacillary load both in lungs and spleen in comparison to
the unvaccinated animals [1.6 log10 and 1.1 log10 fewer bacilli in
lungs (p,0.001) and spleen (p,0.01), respectively] (Fig. 9).
Figure 6. Influence of a-crystallin based prime boost vaccina-
tion on pulmonary fibrosis following M. tuberculosis infection.
The figure depicts representative photomicrographs of Van Gieson
stained lung sections of guinea pigs euthanized at (A) 10 weeks and (B)
16 weeks post-infection. (A) Unvaccinated animals showed extensive
fibrosis characterized by widespread presence of thick bands of
collagen fibers (red color) in the granulomatous areas; BCG and
rBCGacr vaccinated animals showed a moderate staining with the
presence of thin bands of collagen. Animals vaccinated with R/D
regimen showed no evident signs of collagen staining other than the
usual occurrence of collagen in the peri-bronchial and peri-vascular
areas. (B) Unvaccinated animals and BCG vaccinated animals showed
similar staining pattern as observed at 10 weeks; rBCGacr and R/D
vaccinated animals showed negligible staining. Scale bar represents
1 mm. Extent (Q) of pulmonary fibrosis was measured by light
microscopy [Q= Intensity (I)6area (A) of staining] and represented
graphically as median (6 inter quartile range). R/D, rBCG prime –
DNAacr boost. (*, p,0.05; **, p,0.01, when compared to the
unvaccinated animals, Mann-Whitney U test).
doi:10.1371/journal.pone.0018773.g006
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Moreover, the magnitude of protection conferred by R/D
regimen remained significantly higher in comparison to BCG
vaccination at 10 weeks post-infection (with 0.5 log10 and 0.65
log10 fewer bacilli in both lung and spleen, p,0.05), (Fig. 9). At this
time point, although, BCG as well as rBCG vaccination resulted in
a significant reduction in lung bacillary load when compared to
sham immunization [1.1 log10 (p,0.01) and 1.57 log10 (p,0.001)
fewer bacilli, respectively], the reduction in splenic bacillary load
was statistically significant only in case of rBCG group (0.77 log10,
p,0.05).
Altogether, the observations in the murine model indicate that
the induction of a multifunctional Th1 cell response by R/D
regimen significantly contributes to the enhanced protection
against M. tuberculosis infection.
Discussion
Latency associated antigens have been proposed to be
prospective candidates for vaccine development against TB,
however, only a few studies to date have explored the vaccine
potential of such antigens [16,17,18,19]. In this study, we
evaluated the protective efficacy of a heterologous prime boost
approach targeting a-crystallin - a key latency-associated antigen
against TB. We show that the prime boost approach based on a-
crystallin provides a superior and extended protection against M.
tuberculosis infection in guinea pigs. The pathology and cytokine
expression data from guinea pigs support the protective potential
of a-crystallin based prime boost approach. Further, the findings
in murine model provide evidence for the importance of multi-
functional CD4 Th1 response in protection against M. tuberculosis
infection. Vaccination with R/D regimen not only induces a
heightened multi-functional CD4 Th1 cell response, but also
demonstrates a significant control on the bacillary multiplication in
the early as well late phase of infection.
Two main caveats of BCG vaccine are related to its variable
efficacy and inability to impart sterilizing immunity against M.
tuberculosis infection resulting in a large pool of latently infected
individuals. In a recent study, Henao-Tamayo and colleagues
reported that generation of inadequate central memory T cell
response by BCG vaccine renders the host susceptible to TB
infection or reactivation at the onset of adulthood [20]. In
addition, Vekemen et al. indicated that inability of BCG to provide
sterilizing immunity against primary M. tuberculosis infection may
also stem from the inadequate immune response that it generates
against latency associated antigens, such as a-crystallin [5]. Since,
a majority of active TB cases emerge from the reactivation of
latent infections, the need for targeting the latency-associated
antigens for the development of new vaccines against TB cannot
be over emphasized [1]. Here, we demonstrate that enriching
BCG with latency antigen a-crystallin and subsequently boosting
the immunity in an antigen specific manner not only results in an
efficient CD4 Th1 response but also imparts a significantly
superior protection over the conventional BCG vaccination.
Vaccination induced alterations in the cytokine milieu dictate
the outcome of the infection [21]. In this study, for the first time, a
new TB vaccine regimen has been evaluated to analyze the
association between five prominent cytokines and vaccine induced
protection in guinea pigs, to provide an understanding about how
the dynamics of pulmonary cytokine profile influences the fate of
an infection. While, the levels of IFNc or TNFa alone did not
provide any apparent association with the degree of protection
conferred by different vaccine regimens, changes in the levels of
other pro- and anti-inflammatory cytokines, such as IL12, IL10
and TGFb provided a distinct association of these cytokines with
the observed protection. A notable observation in the unvacci-
nated and BCG vaccinated animals was the dysregulation of
TNFa and IFNc expression with time, resulting in an exacerba-
tion of pathology as was evident from an increased granulomatous
inflammation and necrosis in the lungs. However, the expression
of immuno-regulatory or anti-inflammatory cytokines like IL10
and TGFb remained unaltered in these groups. In contrast, the
animals vaccinated with a-crystallin based R/D regimen, although
exhibited similar up-regulation of TNFa and IFNc, their influence
was countered stringently by a commensurate up-regulation of
anti-inflammatory cytokines (IL10 and TGFb), thereby preventing
collateral pathological damage. In addition to these cytokines,
IL12 also exhibited a close association with the degree of
protection. Thus, these observations suggest that an increase in
Figure 7. a-crystallin based prime boost vaccination induces dynamic changes in the cytokine milieu in lungs. Expression of various
cytokines was measured in the lung tissues of vaccinated and saline treated guinea pigs at (A) 10 weeks and (B) 16 weeks post-infection by semi-
quantitative real time RT-PCR by using gene specific primers. The data were normalized to 18S rRNA levels and then normalized to the values of
uninfected animals to obtain DDCt values. The % fold induction values were measured [22DDCt6100] and were graphically represented as mean (6
SE). For cytokine measurement, 3 lung samples were chosen randomly from each group. R/D, rBCG prime – DNAacr boost. (*, p,0.05 and **, p,0.01,
when compared to the saline group, One-way ANOVA).
doi:10.1371/journal.pone.0018773.g007
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the levels of IL12 as well as anti-inflammatory cytokines, such as
TGFb and IL10 from 10 weeks to 16 weeks post-infection are
perhaps crucial for the extended protection and a concomitantly
reduced pathology observed in the case of R/D regimen. These
observations support a previous study that has shown a significant
reduction in bacillary load and increased survival of animals on
administration of IL12 following M. tuberculosis infection [22]. The
enhancement in the levels of anti-inflammatory cytokines like
IL10 and TGFb has also been reported to be essential for the
resolution of granulomatous inflammation making them crucial
for alleviation of disease symptoms (reviewed in [23]). Our
findings are also in coherence with previous studies, which have
demonstrated that if the production of TNFa is not counteracted
by anti-inflammatory cytokines, it results in massive lung
destruction and ultimately death as observed in the case of
unvaccinated animals [10,21,24,25,26]. A seminal study by Ly et
al [21] demonstrated that one of the key elements in the
protection of guinea pigs by BCG vaccination relates to
production of IFNc along with TNFa post-infection in compar-
ison to the unvaccinated animals, wherein, excessive quantities of
TNFa are produced in the absence of IFNc resulting in an
inefficient control of bacillary growth accompanied by excessive
pathology. However, once, BCG vaccinated animals control the
bacillary multiplication, prominence of TGFb mRNA was
observed at the lesion sites, which was accompanied by resolution
of pathology [21]. Although, these associations in our study were
deduced from the measurement of mRNA levels and not by the
direct measurement of cytokines at protein level, they do suggest
potential involvement of these cytokines in mediating protection
against TB. Moreover, several studies have employed real time
RT-PCR for cytokine measurement in case of guinea pigs for
which immunological reagents are still unavailable [21,27]. These
findings in guinea pig model advocate that the measurement of a
battery of cytokines, rather than a single cytokine, such as IFNc is
more likely to provide an appropriate association with vaccine-
induced protection.
Recent studies have emphasized that diseases, such as
tuberculosis, leishmaniasis and HIV/AIDS, which particularly
require Th1 response for an efficient control, rely considerably on
the presence of multi-functional memory and effector T cells
[28,29,30]. Our observations in murine model further indicate
potential involvement of multifunctional (3+) CD4 Th1 cell
response in conferring protection against M. tuberculosis infection
by R/D vaccination. Moreover, induction of a larger repertoire
of both TNFa+IL2+ and IFNc+TNFa+ 2+ CD4 T cells by R/D
regimen perhaps provides a reservoir of long-term central
Figure 8. Induction of CD4 Th1 cell responses by R/D immunization. At 12 weeks post-immunization, T lymphocytes were purified from PPD
and a-crystallin stimulated splenocytes (pooled from four mice per group) and stained for cell surface marker (CD4) along with intracellular staining
for IFNc, TNFa and IL2 followed by FACS analysis. Frequency of IFNc, TNFa and IL2 producing cells was determined on CD4 T cell gated population.
(A) Total frequency (%) of PPD and a-crystallin specific cytokine producing CD4 T cells in spleen. (B) Frequency (%) of PPD and a-crystallin specific CD4
T cells expressing each of the seven combinations of IFNc, TNFa and IL2. (C) Proportion of PPD and a-crystallin specific CD4 T cells producing one,
two or three cytokines. (D) Frequency (%) of PPD and a-crystallin specific 3+ CD4 T cells in spleen along with MFI and iMFI for IFNc, TNFa and IL2. R/D,
rBCG prime – DNAacr boost.
doi:10.1371/journal.pone.0018773.g008
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memory CD4 T cells as well as a pool of effector cells. In
contrast, BCG vaccination, which results in a relatively lower
proportion of 3+ and 2+ cytokine producing CD4 T cells, is
limited in its ability to mediate an efficient and sustained
protection. Although, the data from mice study, wherein we
analysed the immunological responses on pooled samples need to
be interpreted cautiously, it does indicate a crucial role of
multifunctional CD4 T cell response against M. tuberculosis
infection. Moreover, these findings are in coherence with a
seminal study, which indicated that it is the ability of Th1 cells to
produce multiple cytokines, which determines the potency of
these cells in mediating protection against intracellular infections,
such as Leishmania major and M. tuberculosis [29]. Although, caution
should be exercised to extrapolate the mouse immunogenicity
data to guinea pigs due to inherently different response of the two
species to M. tuberculosis infection and a formal demonstration of
the involvement of multifunctional T cells in mediating
protection in guinea pigs is still awaited due to the unavailability
of immunological regents for guinea pigs, the immunogenicity
and protective efficacy studies in murine model do indicate a
crucial role of multifunctional Th1 cell response in mediating
protection against TB.
The ‘rBCG prime - DNA boost’ regimen employed in this
study provides multiple advantages and possibilities in terms of
its clinical relevance. Firstly, in this regimen, the use of rBCG in
place of BCG in newborn children will not only preserve the
valuable attributes of BCG, but will also result in an efficient
immune response and superior protection against pulmonary
TB. Secondly, a booster dose of DNA vaccine would further
enhance and sustain the rBCG-induced immunity. In a
significant finding, Pathan et al. reported that the immunomod-
ulatory effect of an efficient booster vaccine remains unaltered
irrespective of the time span between the primary BCG
vaccination and boosting as these investigators found no
significant difference in the magnitude of immune responses
generated, when the booster was administered a few months or
many years after BCG vaccination [31]. Hence, the advantage of
boosting with DNAacr witnessed in this study can be exploited at
any appropriate age. Thirdly, induction of a-crystallin specific
memory immunity will aid in the enhanced recognition and
clearance of latent bacilli. Hence, vaccination with ‘rBCG prime
- DNA boost’ regimen based on a-crystallin is likely to reduce
the incidence of latent and reactivation TB. While, further
studies would be required to demonstrate these plausible
advantages, a successful demonstration of a-crystallin based
heterologous prime boost vaccination approach in guinea pig as
well as mouse model definitely provides a paradigm to explore
the potential of latency antigens for developing prophylactic and
therapeutic vaccines against TB.
Materials and Methods
Ethics statement
Guinea pig experiments were reviewed and approved by the
Institutional Animal Ethics Committee of National JALMA
Institute for Leprosy & Other Mycobacterial Diseases, Agra,
India (Permit number: 101/1997/CPCSEA). Mice experiments
were reviewed and approved by the Institutional Animal Ethics
Committee of University of Delhi South Campus, New Delhi,
India (Permit number: 159/1999/CPCSEA). All animals were
routinely cared for according to the guidelines of CPCSEA
(Committee for the Purpose of Control and Supervision on
Experiments on Animals), India.
Bacterial strains, animals and preparation of antigens for
immunization
For preparation of rBCGacr, a Mycobacteria - Escherichia coli
shuttle plasmid pSD5.pro [32,33] was engineered to over-express
a-crystallin gene (Rv2031c) under the transcriptional control of
the promoter of hsp65 gene of M. leprae. Briefly, the gene encoding
a-crystallin (Rv2031c) was PCR amplified by using M. tuberculosis
H37Rv genomic DNA as the template and gene specific primers
(forward- 59gggcatcatatggccaccaccc 39 and reverse- 59gggacgcgt-
cagttggtggaccggatgtg 39). The PCR amplicon was then cloned
into pSD5.hsp65 at Nde I and Mlu I restriction sites and the
resulting construct was designated as pSD5.hsp65.acr. The
recombinant plasmid was electroporated into wild type M. bovis
BCG and selected on MB7H11 plates containing Kanamycin
(25 mg/ml).
M. tuberculosis (H37Rv strain), M. bovis BCG (Danish strain) and
rBCG cells were grown to mid-log phase in Middle Brook 7H9
media and stocks were prepared as described [9]. DNA vaccine,
pAK4-acry - expressing a-crystallin was prepared as described [6].
Outbred guinea pigs (Dunkin Hartley strain, female, 200–300 g)
were procured from Disease Free Small Animal House Facility,
HAU, India and maintained in the BSLIII facility at National
JALMA Institute for Leprosy & Other Mycobacterial Diseases,
Agra, India. Mice (Balb/c strain, female, 6–8 weeks) were
procured from National Centre for Laboratory Animal Science,
Hyderabad, India and maintained in the BSLIII facility at
University of Delhi South Campus, New Delhi, India.
In vitro growth of BCG and rBCG
BCG and rBCG were grown in MB7H9 broth supplemented
with 16ADC and 0.2% Tween 80. Growth was assessed at the
intervals of 24 hr for 19 days by measuring the absorbance of the
culture spectro-photometrically at a wavelength of 600 nm
(A600 nm).
Figure 9. a-crystallin based vaccination provides protection
against M. tuberculosis challenge in mice. Mice were infected 12
weeks after primary immunization and euthanized at 2, 4 and 10 weeks
post-infection and lung and spleen bacillary load were determined.
Log10 CFU is graphically represented by box plot (notations are
described in the legend of Fig. 1). Animals vaccinated with R/D regimen
exhibited a significantly lower bacillary load in lung and spleen when
compared to the unvaccinated as well as BCG vaccinated animals at
2, 4 and 10 weeks post-infection. R/D, rBCG prime – DNAacr boost.
(*, p,0.05, **, p,0.01 and ***, p,0.001, when compared to the saline
group, One-way ANOVA).
doi:10.1371/journal.pone.0018773.g009
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Immunization of guinea pigs and evaluation of
protective efficacy against M. tuberculosis infection
For evaluation of protective efficacy two guinea pig experiments
were carried out. Guinea pigs in groups of 5–6 were immunized
with the following regimens: (i, ii) 56105 CFU of either BCG or
rBCG in 100 ml of saline by i.d. route, (iii, iv) rBCG once, followed
by a booster dose of DNA vaccine or vector (100 mg in 100 ml of
saline) by i.m. route at 6 weeks (R/D and R/V) and (v) 100 ml of
saline by i.d. route (control group). Guinea pigs were infected 12
weeks after the primary immunization with ,50–100 bacilli of
virulent M. tuberculosis H37Rv via the respiratory route in an
aerosol chamber (Glasscol Inc.).
Animals were monitored regularly for change in body weight
and general body condition as an indicator of disease progression
and were euthanized at 10 weeks (Exp-I, n = 5) and 16 weeks (Exp-
II, n = 6) post-infection by intraperitoneal injection of Thiopen-
tone sodium (100 mg/kg body weight) (Neon Laboratories Ltd.).
After dissecting the animals, lung, liver and spleen were examined
for gross pathological changes and scored by using the Mitchison
scoring system [34] with minor modifications as described
previously [9]. For histopathological evaluation, three lung lobes
(right caudal, middle and cranial) and a portion of left dorsal lobe
of liver were removed and fixed in 10% buffered formalin. Left
caudal lung lobe and cranial portion of spleen were aseptically
removed for the measurement of bacillary load. Lung and spleen
bacillary load were measured along with the evaluation of
histopathological changes as described [9]. The detection limit
in case of both lung and spleen CFU was 1.0 log10 CFU/g. For
isolation of RNA to be used for real time RT-PCR studies, a
portion of left cranial lung lobe was stored in RNA later (Ambion)
at 220uC.
Immunohistochemistry and image analysis
For in situ localization of M. tuberculosis antigens in the sections of
guinea pig lungs, immunohistochemical (IHC) staining was carried
out and analysed for area and intensity of staining as described
earlier [9].
RNA isolation and real time RT-PCR
Real time PCR was performed by using SYBR green PCR
Master Mix (Applied Biosystems) by using the cDNA synthesized
from total RNA isolated from the lungs of guinea pigs as described
[9]. Sequences of the primers for guinea pig IFNc, TNFa, TGFb,
IL10, IL12 and 18S rRNA were as described [9,35].
Evaluation of protective efficacy and immune responses
in mice
To further confirm the protective efficacy observed in guinea
pig experiments, we carried out a similar protection study in
mouse model. Mice in groups of 4 were immunized and infected
following the same protocol as used for guinea pigs. At 2, 4 and 10
weeks post-infection, bacillary load in lungs and spleen was
determined. Immune responses were evaluated at 12 weeks post-
immunization (at the time of infection).
Cell Isolation, stimulation and flow cytometry
Spleen cells were isolated as described [13] and cultured in
RPMI-GlutaMAXTM (containing 10% heat inactivated FBS and
16antibiotic-antimycotic) (Invitrogen). Cells were then stimulated
with PPD (20 mg/ml) (Statens Serum Institut) or purified a-
crystallin (40 mg/ml) in RPMI for 2 hr at 37uC. GolgiStop was
added according to the manufacturer’s instruction and cells were
incubated for an additional 4 hr before intracellular cytokine
staining.
Following stimulation, cells were washed with PBS containing
2% heat inactivated FBS and T lymphocytes were purified by
using BD IMagTM Mouse T Lymphocyte Enrichment Kit
according to the manufacturer’s instructions. Briefly, a cocktail
of biotinylated antibodies were added to the cells that
simultaneously bind erythrocytes and leukocytes but not T
lymphocytes. The cells were then washed to remove excess
antibodies followed by the addition of BD IMagTM Streptavidin.
Unlabelled T lymphocytes were then enriched by negative
selection by placing them within the magnetic field of the BD
IMagnetTM as per the manufacturer’s instructions. Cells were
washed and incubated with BD Fc BlockTM (CD16/CD32 mAb
to block Fc binding). Subsequently, the cells were stained for cell
surface markers, CD4 (FITC) or CD8 (FITC) along with
intracellular cytokines, IFNc (RPE), TNFa (PerCPCy5.5) and
IL-2 (APC) by using the BD Cytofix/Cytoperm kit according to
the manufacturer’s instructions. Cells were washed twice with
Cytoperm and finally resuspended in sheath fluid. Cells (50,000–
100,000) were acquired by using a FACS Calibur flow-cytometer
(by using Cell Quest Pro software) and analyzed by using FlowJo
software (Tree Star). Cell frequency, median fluorescence
intensity (MFI) and integrated MFI (iMFI =% frequency6MFI)
for different cytokines were calculated. For cell stimulation and
FACS analysis, cells pooled from all 4 mice from a group were
used. All the reagents for cell isolation and antibodies for FACS
staining were obtained from BD Pharmingen, except where
mentioned otherwise.
Statistical analysis
For the comparison of CFU and % fold induction in mRNA
expression level, One-way ANOVA was carried out followed by
Tukey Test. Non-parametric Mann-Whitney U test were em-
ployed for the comparison of gross pathological score, granuloma
% and IHC score. Differences were considered significant, when
p,0.05. For statistical analysis SPSS (Version. 10.0, SPSS Inc.)
and Prism 5 software (Version 5.01; GraphPad Software Inc.) were
used.
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